Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.63 |
| ▸ | NAALAD2 | Q9Y3Q0 | 5/20 | 0.63 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.63 |
| ▸ | GGH | Q92820 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL910469 | 1.00 | FOLH1 (0.63) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| SCHEMBL73336 | 1.00 | FOLH1 (0.63) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| Hydrogen Sulfide SCHEMBL27842653 | 0.98 | FOLH1 (0.61) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| Ammonia Solution, Strong SCHEMBL4947922 | 0.98 | FOLH1 (0.61) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| Sarcosine SCHEMBL28423014 | 0.89 | FOLH1 (0.52) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| Methacrylic Acid SCHEMBL29289351 | 0.89 | FOLH1 (0.52) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| D-Glutamate SCHEMBL28443756 | 0.89 | GRM8 (0.62) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| Acrylic Acid SCHEMBL28279497 | 0.89 | FOLH1 (0.52) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| SCHEMBL12019171 | 0.88 | FOLH1 (0.48) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL27653325 | 0.86 | FOLH1 (0.49) | FOLH1NAALAD2RIMKLAGGHCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114907446-A | Matrix metalloprotease cleavable and serine protease cleavable substrates and methods of use thereof | 西托姆克斯治疗公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-101969920-A | Parakeratosis inhibitor, pore shrinking agent or agent for preventing or improving rough skin, and composition for external use on the skin containing the same | SHISEIDO CO LTD | 2011-02-09 | — | — | CN | disclosed |
| US-20110004019-A1 | Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same | SHISEIDO COMPANY LTD. (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-2255780-A1 | PARAKERATOSIS INHIBITOR, PORE SHRINKING AGENT OR AGENT FOR PREVENTING OR IMPROVING ROUGH SKIN, AND COMPOSITION FOR EXTERNAL USE ON THE SKIN CONTAINING THE SAME | Shiseido Company, Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| CN-1956742-A | Absorbable biocompatible materials | BIOINTERACTIONS LTD (GB) | 2007-05-02 | — | — | CN | disclosed |
| EP-0732933-B1 | USE OF IGF-1 AND IGFBP-3 IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING A RENAL DISORDER | CELTRIX PHARMA (US) | 2002-10-09 | — | — | EP | disclosed |
| US-5723441-A | Method of treating renal disease by administering IGF-I and IGFBP-3 | CELTRIX PHARMACEUTICALS, INC. (US) | 1998-03-03 | — | — | US | disclosed |
| EP-0732933-A4 | — | — | 1996-11-06 | — | — | EP | disclosed |
| EP-0732933-A1 | METHOD OF TREATING RENAL DISEASE BY ADMINISTERING IGF-I AND IGFBP-3 | CELTRIX PHARMACEUTICALS, INC. (US) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995013824-A1 | METHOD OF TREATING RENAL DISEASE BY ADMINISTERING IGF-I AND IGFBP-3 | CELTRIX PHARMACEUTICALS, INC. (US) | 1995-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110004019-A1 | Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same | CUTA, GLRA3, ARGLU1 | FOLH1 4099/4885NAALAD2 1692/4885RIMKLA 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.